{"success":true,"data":{"pressRelease":{"id":"155840","rtpr_id":"nBw9RJ4t9a-20260929","ticker":"QURE","exchange":"NASDAQ","all_tickers":["QURE","UQ1"],"title":"QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law","author":"Business Wire","published_at":"2026-09-29T17:28:00.080Z","article_body":"QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with\nSBS Law\n\nSchall, Brown & Schwartz\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=Schall%2C+Brown+%26+Schwartz&index=1&md5=fc11d64f227492c30bf7753c4d8bcac9)\nLLP (“SBS”), a national shareholder rights litigation firm, announces that\nit is investigating claims on behalf of investors of uniQure N.V.\n(“UniQure” or “the Company”) (NASDAQ: QURE\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FQURE&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=QURE&index=2&md5=6ca556b770f381c7dcba66ce05666235)\n) for violations of the securities laws.\n\nINVESTIGATION DETAILS: The investigation focuses on whether the Company issued\nfalse and/or misleading statements and/or failed to disclose information\npertinent to investors. UniQure provided a four-year update for its gene\ntherapy for patients with Huntington's disease on September 29, 2026.\nInvestor’s Business Daily reports that “After three years, the gene\ntherapy slowed disease progression by 80%. At the four-year mark, though, that\nfell to 44%. The results weren't statistically significant. RBC Capital\nMarkets analyst Luca Issi called the results 'clearly mixed,' while Leerink\nPartners analyst Joseph Schwartz cautioned there are some nuances in the\ndata.” Based on this news, shares of UniQure fell by more than 38.4% in\nmorning trading on the same day.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2Fcases%2Funiqure-n-v-3%2F&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=click+here+to+participate&index=3&md5=b7abab5123e2351090c4c81a18536ad5)\n.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fpr.report%2FmIwBkOrU&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=www.schallfirm.com&index=4&md5=8f5bf5276b7224a05c9ee84d2982e752)\n, or by email at david@schallfirm.com (mailto:david@schallfirm.com) .\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the\nworld and specializes in securities class action lawsuits and shareholder\nrights litigation. Bringing together the extensive experience and diverse\nskillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz,\nSBS is dedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260929585449/en/\n(https://www.businesswire.com/news/home/20260929585449/en/)\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.schallfirm.com&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=www.schallfirm.com&index=5&md5=9a6867164bdeb5a6d5f9b71e38308ba3)\n\nOffice: 310-301-3335\ninfo@schallfirm.com (mailto:info@schallfirm.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw9RJ4t9a-20260929","title":"QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law","author":"Business Wire","ticker":"QURE","created":"2026-09-29T17:28:00.080Z","tickers":["QURE","UQ1"],"exchange":"NASDAQ","article_body":"QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with\nSBS Law\n\nSchall, Brown & Schwartz\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=Schall%2C+Brown+%26+Schwartz&index=1&md5=fc11d64f227492c30bf7753c4d8bcac9)\nLLP (“SBS”), a national shareholder rights litigation firm, announces that\nit is investigating claims on behalf of investors of uniQure N.V.\n(“UniQure” or “the Company”) (NASDAQ: QURE\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FQURE&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=QURE&index=2&md5=6ca556b770f381c7dcba66ce05666235)\n) for violations of the securities laws.\n\nINVESTIGATION DETAILS: The investigation focuses on whether the Company issued\nfalse and/or misleading statements and/or failed to disclose information\npertinent to investors. UniQure provided a four-year update for its gene\ntherapy for patients with Huntington's disease on September 29, 2026.\nInvestor’s Business Daily reports that “After three years, the gene\ntherapy slowed disease progression by 80%. At the four-year mark, though, that\nfell to 44%. The results weren't statistically significant. RBC Capital\nMarkets analyst Luca Issi called the results 'clearly mixed,' while Leerink\nPartners analyst Joseph Schwartz cautioned there are some nuances in the\ndata.” Based on this news, shares of UniQure fell by more than 38.4% in\nmorning trading on the same day.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2Fcases%2Funiqure-n-v-3%2F&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=click+here+to+participate&index=3&md5=b7abab5123e2351090c4c81a18536ad5)\n.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fpr.report%2FmIwBkOrU&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=www.schallfirm.com&index=4&md5=8f5bf5276b7224a05c9ee84d2982e752)\n, or by email at david@schallfirm.com (mailto:david@schallfirm.com) .\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the\nworld and specializes in securities class action lawsuits and shareholder\nrights litigation. Bringing together the extensive experience and diverse\nskillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz,\nSBS is dedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260929585449/en/\n(https://www.businesswire.com/news/home/20260929585449/en/)\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.schallfirm.com&esheet=54612901&newsitemid=20260929585449&lan=en-US&anchor=www.schallfirm.com&index=5&md5=9a6867164bdeb5a6d5f9b71e38308ba3)\n\nOffice: 310-301-3335\ninfo@schallfirm.com (mailto:info@schallfirm.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-29T17:28:00.131474229Z","server_sent_at_ms":1790702880131},"received_at":"2026-09-29T17:28:00.183Z","source_url":"https://www.businesswire.com/news/home/20260929585449/en/"},"analysis":{"id":"144558","press_release_id":"155840","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["securities-fraud investigation signaled following a 38.4% single-day share collapse","four-year trial data (44% progression slowing) not statistically significant vs. 80% at three years","possible undisclosed-information allegations around the clinical data update"],"eventType":"legal_litigation","narrative":"Schall, Brown & Schwartz LLP announced it is investigating potential securities-law claims on behalf of uniQure (QURE) investors, alleging the company issued false or misleading statements.\n\nThe investigation follows uniQure's September 29 four-year update on its Huntington's disease gene therapy, in which reported slowing of disease progression fell from 80% at three years to 44% at four years without statistical significance.\n\nShares of uniQure fell more than 38.4% in morning trading on the news; this release itself is law-firm solicitation rather than a company disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation — suppress; the underlying clinical data drop is the real event."},"keyFigures":{"customDimensions":{"share_price_drop":"-38.4%","disease_progression_slowing_year3":"80%","disease_progression_slowing_year4":"44%"}},"quotedText":"After three years, the gene therapy slowed disease progression by 80%. At the four-year mark, though, that fell to 44%. The results weren't statistically significant.","namedEntities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Andrew Brown","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Luca Issi","role":"RBC Capital Markets analyst"},{"name":"Joseph Schwartz","role":"Leerink Partners analyst"}],"products":["gene therapy for Huntington's disease"],"companies":[{"name":"uniQure N.V.","ticker":"QURE","relationship":"subject of investigation / target"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"},{"name":"RBC Capital Markets","relationship":"analyst firm mentioned"},{"name":"Leerink Partners","relationship":"analyst firm mentioned"},{"name":"Investor's Business Daily","relationship":"media source cited"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Schall, Brown & Schwartz announcing an investigation of uniQure securities claims. No certified class, no settlement, no issuer disclosure; the underlying clinical data was already public and priced in (stock fell 38.4% the same day)."},"tickerRelevance":{"others":[],"primary":"QURE"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false,"retailFavoriteBoost":"QURE has retail interest due to Huntington's gene therapy franchise"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Schall, Brown & Schwartz LLP announced it is investigating potential securities-law claims on behalf of uniQure (QURE) investors, alleging the company issued false or misleading statements.\n\nThe investigation follows uniQure's September 29 four-year update on its Huntington's disease gene therapy, in which reported slowing of disease progression fell from 80% at three years to 44% at four years without statistical significance.\n\nShares of uniQure fell more than 38.4% in morning trading on the news; this release itself is law-firm solicitation rather than a company disclosure.","key_figures":{"customDimensions":{"share_price_drop":"-38.4%","disease_progression_slowing_year3":"80%","disease_progression_slowing_year4":"44%"}},"named_entities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Andrew Brown","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Luca Issi","role":"RBC Capital Markets analyst"},{"name":"Joseph Schwartz","role":"Leerink Partners analyst"}],"products":["gene therapy for Huntington's disease"],"companies":[{"name":"uniQure N.V.","ticker":"QURE","relationship":"subject of investigation / target"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"},{"name":"RBC Capital Markets","relationship":"analyst firm mentioned"},{"name":"Leerink Partners","relationship":"analyst firm mentioned"},{"name":"Investor's Business Daily","relationship":"media source cited"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T17:28:06.507Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false,"retailFavoriteBoost":"QURE has retail interest due to Huntington's gene therapy franchise"}},"durationMs":6308,"modelName":"glm-5.3-flashx"}}